|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,296 GBX | -0.87% |
|
+1.54% | +16.00% |
| 02:06pm | Innate Pharma: five abstracts selected for ASCO | CF |
| 02:07am | Adherium Partners with AstraZeneca for Hailie Smartinhaler Trial | MT |
On May 6, 2024, Cellectis S.A., closed the transaction. As the result of the transaction, AstraZeneca PLC, now owns approximately 44% of the share capital and 30% of the voting rights of the company.
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 12,296 GBX | -0.87% | +1.54% | 244B | ||
| 2.51 EUR | -3.46% | -5.10% | 281M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +16.00% | 244B | |
| +38.86% | 728B | |
| +33.05% | 603B | |
| -5.54% | 360B | |
| +18.74% | 332B | |
| +1.41% | 279B | |
| +8.09% | 207B | |
| -5.77% | 205B | |
| +6.43% | 164B | |
| -0.27% | 122B |
ASTRAZENECA PLC 
